Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on August 24, 2022, regarding an event that occurred on August 19, 2022. The filing addresses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director compensation and appointment details.
Material Changes
The Board of Directors expanded its size from ten to eleven members. Dr. Elliott Sigal was elected to fill the newly created vacancy, effective August 22, 2022. He serves as a Class I director with a term expiring at the 2023 annual meeting of stockholders.
Compensation and Governance Details
- Annual Cash Fee: Dr. Sigal will receive $55,000 annually as a non-employee director.
- Initial Stock Option Grant: On August 22, 2022, Dr. Sigal received an option to purchase 4,456 shares of common stock.
- Grant Date Fair Value: $600,000.
- Exercise Price: $217.91 per share.
- Vesting Schedule: Ratably in three annual installments beginning one year after the grant date.
- Future Annual Awards: Beginning in 2023, Dr. Sigal is eligible for an annual stock option award with a target grant date fair value of $400,000, vesting in full one year after the grant date.
- Other Benefits: The Company will reimburse reasonable travel and related expenses. An indemnification agreement was also executed.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the 4,456 new options on potential dilution.
- Confirm the current market price of ALNY stock relative to the $217.91 exercise price to assess the intrinsic value of the grant.
- Review the Company's proxy statement for details on the Nominating and Corporate Governance Committee's recommendation process.
- Check subsequent filings for the vesting status of the initial grant and the details of the 2023 annual award.